Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Botswana
  Brazil
  Bulgaria
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Finland
  France
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lichtenstein
  Lithuania
  Luxembourg
  Madagascar
  Malta
  Mexico
  Montenegro
  Morocco
  Namibia
  Netherlands
  Nigeria
  Norway
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tanzania
  Tunisia
  Turkey
  Uganda
  Ukraine
  United Kingdom
  United States


   Infocentre

Last Update: 19-09-2011  
Related category(ies):
Health & life sciences

 

Add to PDF "basket"

Researchers identify two-tier system in brain tumours

An international team of researchers has discovered that the second most common type of malignant brain tumour in children is ependymomas. The finding is part of a large molecular-genetic study of ependymomas of the cerebellum. Presented in the journal Cancer Cell, the study reveals that based on the anomalies of their genetic material, ependymomas of the cerebellum are classified in two distinct subgroups: group A ependymomas, and group B ependymomas. The former assume negative characteristics while the latter have a positive prognosis.

Assessing tumours in brain © Shutterstock
Assessing tumours in brain
©  Shutterstock

Ependymoma emerges from precursor cells of the central nervous system tissue that lines the hollow cavities of the brain. Treatments to fight this tumour have varying results. Some patients' conditions are improved by surgery and radiotherapy, which help stop the tumour from growing, while others suffer from a disease that moves quickly and severely. Around 50% of children contend with tumours that continue to grow, and some of them die from it.

'It is the patients with a severe course, in particular, who urgently need better therapies,' explains Dr Stefan Pfister, a researcher at the German Cancer Research Center (DKFZ) and Heidelberg University Hospitals, who cooperated with colleagues from Canada, Italy, Poland, Russia and the United States.

The team assessed the activity of individual genes in 583 tissue samples. They investigated the genetic material for losses or gains of whole deoxyribonucleic acid (DNA) segments. The researchers performed independent assessments of the two tumour groups; the results were then validated on the tissue samples of a third group. According to the team, doing this enabled them to obtain valuable results.

They point out that group A tumours have relatively few losses or gains of gene segments. But a number of genes that influence key cancer signalling pathways are activated. On the one hand, group A tumours often metastasise and patients usually die. Group B tumours, on the other hand, offer more hope to patients despite the fact that the genome of these cancer cells is not very stable. Experts say typical characteristics are gains of large segments of chromosomes 9, 15 and 18, and losses of chromosomes 6 and 22.

'The genetic differences between these two types are so marked that we have to speak of two different diseases that may even arise from different original cells,' Dr Pfister says.

The German group plans to investigate this matter further. They will assess group A ependymomas to find out which of the genetic alterations are so-called driver mutations, the mutations that trigger the production of cancer cells. Further work will help researchers identify potential targets for improved drugs capable of fighting group A tumours.

It should be noted that researchers have already developed targeted drugs for a number of signalling pathways that are hyperactive in group A ependymomas. Clinical trials are now testing these drugs for other cancer types. The team says it is likely that several of these substances could be viable for treatment against ependymomas.


Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Cancer Cell
German Cancer Research Center (DKFZ)
'Scientists drive cancer genome decoding initiative'





  Top   Research Information Center